Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

September 23, 2024 7:04 AM UTC Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $106.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented: "After ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login